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measurement (16 items, 5-point Likert-scale) as well as DCE (8
pairs with 8 characteristics). The DCE pairs were generated at
random. Analyses of variance, inﬂuencing factors, random effect
probit and logit models for the DCE were performed. RESULTS:
282 patients responded of which 54% were male: mean age 62
years (SD = 10 years), mean duration of the disease ﬁve years
(SD = 3.8 years). Direct measurement revealed efﬁcacy aspects
and further treatment options as most important followed by
prolonged life expectancy, less side effects, therapy-free-intervals
and ﬂexibility. All aspects showed mean values above 50 points
(scale 0–100). In the DCE, alternatives which especially con-
tained one or more of the aspects further treatment options,
longer life expectancy, “Not-always-think-of-the-disease” and
therapy-free-intervals were more frequently selected than others.
CONCLUSIONS: Further treatment options are of major impor-
tance to MM patients. In addition, patients value treatment-free-
lifetime and emotional quality especially if they are not
continuously reminded of the disease. Combining direct mea-
surement of patients preferences with choice based measure-
ments like the DCE ensures eliciting important treatment aspects
and avoids ceiling effects and “all-is-very-important” results.
REMARKS: Patient-advocacy-groups Arbeitsgemeinschaft
Plasmozytom/Mulitples Myelom and Deutsche Leukämie- &
Lymphom-Hilfe helped organizing the surveys.
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OBJECTIVES: Prostate cancer is the second leading cause of
cancer mortality in American men. Androgen deprivation
therapy (ADT) is the standard initial treatment for advanced
disease, but most patients eventually develop HRPC. There are
no universally accepted, standardized and objective criteria for
assessing response to treatment for HRPC, so patient-reported
outcomes (PRO) are a critical in guiding and monitoring pallia-
tive interventions. We characterized the prevalence and natural
history of symptoms in patients with hormone refractory, incur-
able prostate cancer. METHODS: Patients with HRPC receiving
care at Dana-Farber Cancer Institute, completed a questionnaire
at each clinic visit over 10 months, comprising the Quality of Life
Index (QLI), Rotterdam Symptom Checklist (RSCL), Brief Pain
Inventory (BPI), Hospital Anxiety and Depression Scale (HADS),
American Urological Association symptom index (AUA), and the
ECOG performance status scale. RESULTS: A total of 87 of 102
eligible patients enrolled. Among participants, the survey
response rate was 98%. A total of 87% had documented
metastases; the remainder had rising prostate speciﬁc antigen
levels despite ADT. The following frequencies of symptoms were
reported at baseline and during follow-up (worst scores ever),
respectively: urinary symptoms, moderate/severe: 62 v. 75%; any
pain, 67 v. 70%; severe intensity in worst pain score, 19 v. 25%;
HADS possible/probable diagnosis: anxiety, 21 v. 39%, depres-
sion, 20 v. 35%; ECOG PS 2+, 15 v. 37%; RSCL symptoms:
tiredeness, 30 v. 60%; lack of energy, 28 v. 58%; muscle soreness,
26 v. 45%. The mean overall health rating (0 = worst,
100 = best) was, 74 at baseline v. 56 during follow up. A shift
toward lower levels of HRQL was also observed across all
domains of the QLI. CONCLUSIONS: Patients with HRPC
endure a substantial and worsening symptom burden over time.
Given the high prevalence of symptoms and difﬁculty of assessing
treatment response by objective measures in this disease, PRO
should be routinely incorporated into clinical care and trials.
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OBJECTIVES: Panitumumab, a fully human anti-EGFr mono-
clonal antibody, is approved in Europe as monotherapy for
mCRC patients with wild-type (non-mutated) KRAS tumors. In
a randomized phase 3 trial, chemorefractory mCRC patients
receiving panitumumab plus BSC had signiﬁcantly longer
progression-free survival vs. BSC alone. Analyses of the KRAS
gene showed that all responders had wild type KRAS. This
analysis evaluates patient-reported outcomes (PROs) by KRAS
status. METHODS: In the phase 3 trial, mCRC patients with
disease progression after standard chemotherapy were random-
ized 1:1 to panitumumab (6 mg/kg Q2W) plus BSC vs. BSC
alone. KRAS status was assessed in 427/463 (92%) patients.
Analyses of PROs included HRQOL (EQ-5D) and CRC symp-
toms (NCCN/FACT CRC Symptom Index, FCSI). Linear mixed
models estimating change from baseline in PRO scores were
employed. Sensitivity analysis using pattern-mixture models
evaluated the appropriateness of the assumption that PRO data
were missing at random. Pattern-mixture models can provide
unbiased estimates of treatment effects, taking into account
missing data patterns. ANCOVA of the time-adjusted AUC using
last value carried forward (LVCF) and slope imputation methods
were also used. RESULTS: There were 363/427 (85%) patients in
the KRAS-PRO analysis set (188 panitumumab [112 wild-type
KRAS; 76 mutant KRAS]; 175 BSC [96 wild-type KRAS; 79
mutant KRAS]). Linear mixed models showed signiﬁcant differ-
ences in CRC symptoms and HRQOL in favor of panitumumab
in patients with wild-type KRAS. No differences were observed
in patients with mutant KRAS. Pattern-mixture analysis showed
that signiﬁcant differences in CRC symptoms (FCSI scores: dif-
ference in LS adjusted means [95%CI]; 5.746 [1.448, 10.044]
and HRQOL (EQ-5D scores: difference in LS adjusted means
[95%CI]; 0.319 [0.184, 0.454]) in favor of panitumumab treated
patients with wild-type KRAS were particular to patients who
progressed greater or equal to 9 weeks. CONCLUSIONS: Pani-
tumumab patients with wild-type KRAS showed signiﬁcantly
better HRQOL and CRC symptoms compared to BSC alone.
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OBJECTIVES: Even though chemotherapies of advanced
non-small cell lung cancer (NSCLC) are improving patients’ out-
comes, usually patients’ treatment preferences are underesti-
mated by physicians. To identify those attributes related to
chemotherapy treatment that is highly valued by patients
with advanced NSCLC. METHODS: An observational, cross-
sectional study was carried out. A four attributes treatment
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preferences questionnaire was elaborated in a pilot study: treat-
ment mode of administration, time spent in hospital for admin-
istration, immediate toxicity, and level of symptoms control;
distributed in 9 hypothetic scenarios. Second line NSCLC
patients were asked to score by preferred scenario, through the
conjoint analysis method. Socio-demographic, clinical and
health-related quality of life (RSCL) characteristics were col-
lected and linear regression models were performed. RESULTS:
A total of 172 patients were enrolled. Mean (SD) age 61.9 (10.5)
years. Seventy-ﬁve percent were men, 84.8% in NSCLC stage IV,
50% ECOG 1 20.3% of patients received cisplatine +
gemcitabine in ﬁrst line, 30.8% showed treatment’s adverse reac-
tions and 52.9% were scheduled to erlotinib as second line.
Psychological symptoms’ was the most affected RSCL dimension.
The ICC of questionnaire’s scenarios was assessed (0.55–
0.88).The most preferred attribute was symptoms’ control and
the most preferred scenario was: oral administration, no time
spent in hospital, low toxicity and total symptoms’ control (G
scenario). Patients who started oral administration vs patients
who started intravenous administration, gave more utility/
importance to the attributes ‘treatment administration’ (0.30 vs
-0.12) and ‘time spent in hospital’ (0.62 vs 0.45). Psychological
and daily functioning affection, ECOG 1-2 and adverse reactions
in ﬁrst line were related to G scenario. CONCLUSIONS: The
most valued attributes by advanced NSCLC patients are
moderate-total symptoms’ control and oral administration.
Patients with worst functional status and psychological affection
preferred total symptoms’ control, oral administration, no time
spent in hospital and low toxicity. Treatment preference’s ques-
tionnaire showed utility, feasibility and reliability for treatment
decisions, allowing physicians to explore patients’ preferences
before initiating treatment.
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OBJECTIVES: To evaluate whether shared decision making
in treatment selection for cancer differs by race. METHODS:
Newly diagnosed local stage prostate cancer patients and their
family members were recruited following biopsy but prior to
initiating treatment at urology practices in three states to partici-
pate in a take-home survey. RESULTS: A total of 192 family
pairs completed surveys. In 14% of the family pairs, at least one
subject was black, 13% had a Hispanic member, and 66% had
no minority members. Discussions between patients and family
members about treatment options occurred “very” often among
26% of black families, 30% of Hispanic families, 52% of white
families (p = 0.06). Patients reported differences by race in how
extensively physicians involved them (60% among blacks, 79%
among Hispanics, and 49% among whites, p = 0.04). 91% of
family members reported attending physician visits with the
patient; 66% indicated their role was to help the patient make a
treatment choice, 72% reported the physician involved them in
the decision process, and 61% reported “excellent” satisfaction
with the patient’s doctor with no signiﬁcant differences by race.
In multivariate analyses, family members who perceived that the
patient’s physician did not involve them were signiﬁcantly less
likely to be highly satisﬁed (OR = 0.22, 95% CI 0.10–0.48).
CONCLUSIONS: Family members of all races often attended
clinic visits and discussed treatment options with physicians.
Compared to whites, black and Hispanic patients, but not family
members, reported more encouragement by physicians to be
involved in the decision process. Black and Hispanic families
were less likely to discuss treatment options among themselves.
Family member satisfaction was dependent on their perception of
whether the physician involved them in the decision process.
Race may be less of a factor when physicians involve patients and
family members extensively in the treatment decision making
process.
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OBJECTIVES: “Domiciliary palliative care ‘OKAYAMA’ model”
in which specialist palliative care team cooperates with primary
care team, is attracting attention to promote a home palliative
care service in Japan. To evaluate the outcome of this
“OKAYAMA model”, we investigated the satisfaction of the
patients’ family who received the home palliative care service by
this model. METHODS: A survey form consisting of 20 items
from the FAMCARE Scale was then sent to 83 surviving family
members of patients who had received care under this
“OKAYAMA” palliative care model. The study plan was
reviewed and approved by an ethics committee. RESULTS: The
mean score for the survey was 3.94  0.19 points (out of a
possible 5). Responses of “satisﬁed” or better were received by
more than 50% of respondents for nearly all items. The ratings
were high for “pain relief,” “answers from health professionals,”
“availability of doctors to the family,” “doctor’s attention to the
patient’s description of symptoms,” and “availability of the
doctor to the patient.” A positive assessment was made for time
spent and efforts made to respond to the desires of patients’
families following the conclusion of pain control prior to home
palliative care. Conversely, issues remain in items such as “avail-
ability of a hospital bed.” Four factors were identiﬁed in a factor
analysis of the FAMCARE Scale: “adequate amount of informa-
tion,” “attitude of medical personnel,” “education and support
system for families,” and “emergency responses.” Only 44% of
respondents were satisﬁed with the care provided by the respon-
dents themselves as a family member, suggesting the need for
environmental improvements to ease the burden on families.
CONCLUSIONS: The results of this study help us to develop an
appropriate model for a home palliative care system using a
multidisciplinary team approach.
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OBJECTIVES: To elicit treatment preference and WTP for Meth-
ylnaltrexone, a novel peripheral opioid antagonist versus existing
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